Breaks Categories: Stock Spotlights

MondayJan 09, 2023 12:19 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of the most aggressive primary brain cancers. “The drug, Berubicin, is an anthracycline chemotherapy agent that apparently has the unique ability to cross the blood-brain barrier to target tumors directly. The inability of anthracyclines to cross the blood-brain barrier has been identified as a major obstacle in treating aggressive brain tumors such as GBM and creates an opportunity for CNS…

Continue Reading

ThursdayDec 29, 2022 1:20 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market

BiondVax (NASDAQ: BVXV) is focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is developing a pipeline of nanosized antibody (‘NanoAb’) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, psoriasis, asthma, psoriatic arthritis, and wet macular degeneration. The company currently collaborates with the prestigious Max Planck Institute for Multidisciplinary Sciences (‘MPG’) and the University Medical Center Göttingen (‘UMG’), both in Germany,” a recent article reads. “BiondVax is targeting a massive, validated, addressable market with a pipeline of de-risked NanoAbs with a lead…

Continue Reading

WednesdayDec 28, 2022 11:03 am

BioMedNewsBreaks – MetAlert Inc.’s (MLRT) RoomMate(TM) Delivers Efficiency, Privacy for Alzheimer’s, Dementia and ADA Patients

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, recently signed a letter of intent (“LOI”) with Sensio Group, a Norway-based provider of welfare technology and home automation solutions, for the marketing and distribution of RoomMate(TM). “RoomMate, one of MetAlert’s flagship products, is a wall-mounted alert system that delivers both efficiency and privacy. It detects and alerts caregivers about patient behavior that could lead to falls and injuries, using 3D infrared and wall-mounted sensors that eliminate the need for any other physical installations or wearables. Unlike more mainstream patient monitoring systems, RoomMate does not use…

Continue Reading

FridayDec 16, 2022 3:42 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Announces Launch of Game-Changing, Potentially Lifesaving GPS SmartSole in Canada

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, is a solution leader for consumers and patients with needs for remote monitoring. “MetAlert has announced that Canadian distributor Red Dot Alerts has launched the new award-winning 4G GPS SmartSole – a wearable medical monitoring device integrated into the orthotic insole allowing for discreet tracking and remote monitoring for those with Alzheimer’s, dementia and autism. The launch is supported by a marketing and advertising campaign, including radio and magazine ads and mailers to medical clinics, hospitals, pharmacies, and senior residence facilities across Canada. The advertising campaign…

Continue Reading

FridayDec 16, 2022 2:59 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Renowned Cardiologist to Help Define Best Paths to Advance Products

HeartBeam (NASDAQ: BEAT), a cardiac technology company, recently named a world-renowned interventional cardiologist with an impressive breadth of experience as its chief medical officer. “Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help HeartBeam continue to develop the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere… Dr. Fitzgerald joins HeartBeam after gaining invaluable experience in the clinical, research and industry sectors. An accomplished inventor, entrepreneur and investment-fund founder, Dr. Fitzgerald is serving as director of the Center for Cardiovascular Technology and director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School,” a recent article…

Continue Reading

FridayDec 02, 2022 1:19 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Recognized for ‘Unique Approach to Heart Attack Diagnosis’

HeartBeam (NASDAQ: BEAT) was recently named the winner of the annual Cardiovascular Innovations (“CVI”) 2022 Information Summit and Shark Tank Competition, an annual conference that focuses on innovative health solutions for cardiology clinicians. Awards presented at the conference recognize state-of-the-art cardiac technologies. “The company, which has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has made a mark for itself in the cardiac care field by building an intellectual-property portfolio focused on enabling 12-lead ECG diagnostics outside of a medical setting. Most recently, HeartBeam announced that it was issued a new patent, which enables…

Continue Reading

WednesdayNov 23, 2022 3:21 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for glioblastoma multiforme (‘GBM’), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and priorities, Climaco emphasized, are firmly anchored in the advancement of its clinical development for its drug candidate Berubicin with the aim of bringing meaningful treatment to GBM patients. And as he separately told attendees at…

Continue Reading

MondayNov 07, 2022 1:50 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Targeted ‘Finish Line Is Within Sight’ as It Pursues Potential GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) has been developing drug candidates for treating primary and metastatic brain and central nervous system cancer. “Berubicin, the company’s lead drug candidate, is a novel anthracycline in an ongoing international trail in glioblastoma (“GBM”) treatment. The interim analysis data from this potentially pivotal trial is expected in mid-2023… Berubicin was the first [anthracycline] to provide scientific data which appears to demonstrate its ability to cross the blood-brain barrier and was designed with a molecular target of topoisomerase II enzymes responsible for cleaving and recombing double-stranded DNA during cellular replication,” a recent article explains. “Since the beginning…

Continue Reading

ThursdayNov 03, 2022 2:42 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is focused on fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. “Silo Pharma is currently developing ketamine treatments for fibromyalgia – a chronic disease that causes pain throughout the body. With no cure available, fibromyalgia can be a debilitating condition that extends beyond the pain to cause extreme fatigue, anxiety and memory issues. Silo’s novel ketamine formulation, designated as SP-26, is currently undergoing safety evaluation to treat fibromyalgia,” reads a recent article. “We are…

Continue Reading

MondayOct 31, 2022 2:42 pm

BioMedNewsBreaks – Quad M Solutions Inc. (MMMM) Commences Application to Dual List on Upstream

Quad M Solutions (OTC: MMMM), a staffing company providing modern health care solution benefits, today announced that it has begun the application process for dual listing on Upstream, the next-generation trading app for digital securities and NFTs powered by Horizon Fintex (“Horizon”) and MERJ Exchange Limited (“MERJ”). According to the update, the planned dual listing is designed to provide Quad M with the opportunity to access a global, digital-first investor base that can trade using the USDC digital currency along with credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in OTC-listed…

Continue Reading